Several studies have investigated the possible genetic polymorphisms present in patients with NAFLD/NASH and the results obtained have suggested a certain role of IL-6, adiponutrin apolipoprotein C3, and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) (Carulli et al., 2009; Rotman et al., 2010; Petersen et al., 2010), (Sookoian et al., 2010b; Domenici et al., 2013). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.